To include your compound in the COVID-19 Resource Center, submit it here.

FDA removes holds on Genentech's omalizumab

According to DNA partner Tanox (TNOX), the FDA lifted its holds and partial holds

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE